Nasal Glucagon · Baqsimi
Peptide
Evidence outlook
Approved: Severe Hypoglycemia
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
Also approved (1)
- Baqsimi is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 4 years and over with diabetes mellitus.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT03339453 NCT03339453 · Hypoglycemia This randomized, open-label, two-period crossover trial (Study 1 in the BAQSIMI label) compared nasal glucagon 3 mg with intramuscular glucagon 1 mg in 70 adults with type 1 diabetes after insulin-induced hypoglycemia. The primary endpoint was treatment success within 30 minutes, tested for non-inferiority with a margin of -10%. All 66 evaluable patients succeeded with both products (difference 0%, 95% CI -2.9% to 2.9%), so non-inferiority was shown and the primary was met. Source: the BAQSIMI label (openFDA). Registry: NCT03339453 | 1 | Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia (Pre-dose up to 30 minutes post each glucagon administration) 2017-12-17 | Treatment success during insulin-induced hypoglycemia: nasal glucagon 3 mg 66/66 (100%) vs intramuscular glucagon 1 mg 66/66 (100%); difference 0% (95% CI -2.9% to 2.9%), non-inferiority margin -10% (BAQSIMI label, Study 1). | not yet graded | link ↗ |
View 1 more trial
NCT01994746 NCT01994746 · Diabetes Mellitus, Type 1 Registry: NCT01994746 | 3 | Increase in Plasma Glucose Level to >=70mg/dL or an Increase of >=20mg/dL From Glucose Nadir (Within 30 minutes after receiving glucagon at both dosing visits (glucose was measured at pre-dose; 5, 10, 15, 20, 25, and 30 minutes following glucagon administration)) 2015-01 | Increase in Plasma Glucose Level to >=70mg/dL or an Increase of >=20mg/dL From Glucose Nadir (Within 30 minutes after receiving glucagon at both dosing visits (glucose was measured at pre-dose; 5, 10, 15, 20, 25, and 30 minutes following glucagon administration)): Nasal Glucagon (NG) 98.7 percentage of participants | Intramuscular (IM) Glucagon 100 percentage of participants | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (1)
What this study did
Phase 1 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other Glucagon receptor (agonist) drugs
dasiglucagon. Compare all 2 Glucagon receptor (agonist) drugs
1 other tracked programme targets this mechanism, none of them ahead of this one.
This drug's own stage for Severe Hypoglycemia: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Nasal Glucagon (Baqsimi): this drug | Approved | Peptide | Glucagon receptor (agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Dasiglucagon (Zegalogue) | ApprovedUS marketing discontinued | Peptide | Glucagon receptor (agonist) | Partial signal | NCT03378635: Time to Plasma Glucose Recovery (0-45 minutes after dosing): Dasiglucagon 0.6 mg 10 minutes (95% CI 10 to 10) | Placebo 40 minutes (95% CI 30 to 40) | GlucaGen® 1.0 mg 12 minutes (95% CI 10 to 12) NCT03667053: Time to Plasma Glucose Recovery (0-45 minutes after dosing): Dasiglucagon 0.6 mg 10 minutes (95% CI 8 to 12) | Placebo 30 minutes (95% CI 20 to 45) | GlucaGen® 1.0 mg 10 minutes (95% CI 8 to 12) |
Compare side by side
Upcoming events
No upcoming readouts on record for this asset.